Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

BACKGROUND: HER2 expression and amplification are observed in ~15% of tumour biopsies from patients with a sensitising EGFR mutation who develop EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumour responses. METHODS: A single arm phase II study was performe...

Descripción completa

Detalles Bibliográficos
Autores principales: de Langen, Adrianus J., Jebbink, M., Hashemi, Sayed M. S., Kuiper, Justine L., de Bruin-Visser, J., Monkhorst, Kim, Thunnissen, Erik, Smit, Egbert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162232/
https://www.ncbi.nlm.nih.gov/pubmed/30061586
http://dx.doi.org/10.1038/s41416-018-0194-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162232/
https://www.ncbi.nlm.nih.gov/pubmed/30061586
http://dx.doi.org/10.1038/s41416-018-0194-7

Ejemplares similares